Earnings Call Summary | Elutia(ELUT.US) Q4 2023 Earnings Conference
Earnings Call Summary | Elutia(ELUT.US) Q4 2023 Earnings Conference
The following is a summary of the Elutia, Inc. (ELUT) Q4 2023 Earnings Call Transcript:
以下是Elutia, Inc.（ELUT）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Elutia reported a slight increase in net sales in 2023, reaching $24.7 million, primarily due to its proprietary products CanGaroo and SimpliDerm, which grew about 19% year-over-year.
The adjusted gross margin fell to 58% from 63% in the previous year, mainly due to the partnership with LeMaitre Vascular.
The company's adjusted EBITDA was $14.6 million for 2023, showing a decline from $22.9 million in 2022.
At the year-end, the company's cash on hand was $19.3 million, and it expects to add around $16 million through in-the-money warrants.
Elutia報告稱，2023年的淨銷售額略有增長，達到2470萬美元，這主要歸因於其專有產品CangaRoo和SimpliDerm，同比增長約19％。
調整後的毛利率從去年的63％降至58％，這主要是由於與LeMaitre Vascular的合作。
該公司2023年調整後的息稅折舊攤銷前利潤爲1,460萬美元，較2022年的2,290萬美元有所下降。
截至年底，該公司的手頭現金爲1,930萬美元，預計將通過價內認股權證增加約1600萬美元。
Business Progress:
業務進展：
Elutia expects continued growth for CanGaroo and SimpliDerm in 2024.
The company divested its Orthobiologics business and formed a partnership with LeMaitre Vascular for the distribution of cardiovascular products.
Elutia is in the process of gaining clearance for the launch of CanGarooRM, a step that boosts its drug and bleeding biologic pipeline prospects.
Despite a restructuring at its distributor, Sientra, the company anticipates ongoing strong performance from SimpliDerm.
With the completion of the divestiture of its Orthobiologics business, the company gained gross cash proceeds of $14.6 million.
Elutia submitted their 510(k) premarket notification in December 2023 and expects clearance in the first half of 2024.
A strategic advisory committee has been established to support the launch of CanGarooRM, signaling that all is set for a successful launch of the product.
The company is planning to seek approval for more indications post-launch of CanGarooRM, including NeuroStim, Parkinson's disease, sleep apnea, and others.
Elutia預計，CangaRoo和SimpliDerm將在2024年持續增長。
該公司剝離了其骨科業務，並與LeMaitre Vascular建立了分銷心血管產品的合作伙伴關係。
Elutia正在獲得CangaRoorm上市的許可，這一舉措提振了其藥物和出血生物製劑產品線的前景。
儘管其分銷商Sientra進行了重組，但該公司預計SimpliderM將繼續保持強勁的業績。
隨着骨科業務的剝離，該公司獲得了1,460萬澳元的總現金收益。
Elutia於2023年12月提交了510（k）的上市前通知，預計將在2024年上半年獲得許可。
已經成立了一個戰略顧問委員會來支持CangaRoorm的推出，這表明該產品的成功發佈已準備就緒。
該公司計劃在CangaRoorm推出後尋求更多適應症的批准，包括NeuroStim、帕金森氏病、睡眠呼吸暫停等。
More details: Elutia IR
更多詳情： Elutia IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。